ISB News

Six Years In, ISB’s Innovator Award Program an ‘Unqualified Success’ 

Innovator Award Program ROI

Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

The fifth cycle of ISB’s Innovator Award Program officially wrapped up this week with the principal investigators of the 2021-22 projects delivering their final presentations. In April, three 2022-23 Innovator Award collaborative projects were announced. (See the full list of current and former Innovator awardees and projects here.)   

“The Innovator Award Program has been an unqualified success,” said Dr. Nitin Baliga, ISB senior vice president, director and professor. “We created this program in 2017 to drive innovation at ISB and to award cross-cutting projects that bring people from different labs together. The Innovators Program also provides training for participants in grant writing, the preparation of project materials, leading teams, managing budgets, and other tasks that are important for transitioning into an independent career,” he said.

The metrics of the program are impressive. Over five completed cycles, the Innovator Award Program has resulted in 16 funded projects, seven patents filed, 22 papers published, 28 new grant ideas, 35 partnerships created, six software products and nine new methods or technologies. 

In 2021, Washington Research Foundation (WRF) pledged $100,000 to ISB to fund the Innovator Award Program, with ISB securing an additional $50,000 from other sources. WRF matched their pledge for the 2022-23 Innovator Award cycle, as well. 

“We thank WRF for their generous support not only for this program, but for their longtime support of ISB,” Baliga said.

WRF has provided more than $2.7 million in grants and pledges, including support that brought microbiome specialist Dr. Sean Gibbons to ISB in 2018.

Learn more about the program here.

The 2021-22 Innovators final presentations were:

Project: Discerning the combinatorial regulatory circuitry of microglial differentiation in Alzheimer’s disease using probabilistic Boolean networks

Lead investigator: Bahar Tercan, Postdoctoral Fellow (Shmulevich lab)

ISB research team and collaborators: Cory Funk (Hood-Price Lab), Boris Aguilar (Shmulevich Lab) and Max Robinson (Hood-Price Lab)

 

Project: SOMA: Joint spatial omics and metabolic function analysis in single tissue section at single cell sensitivity

Lead investigator: Yin Tang, Postdoctoral Fellow (Wei Lab)

ISB research team and collaborators: Guangrong Qin (Shmulevich Lab), David L. Gibbs (Shmulevich Lab), Hanjun Cheng (Wei Lab) and Xiaoyang Ye (Wei Lab)

External collaborator: Raymond S. Yeung, University of Washington

 

Project: Multiparameter profiling of exosomes from body fluids to detect and determine site of infection

Co-lead investigators: Yue Lu, Postdoctoral Fellow (Heath Lab) and Christopher Lausted (Hood-Price Lab)

ISB research team and collaborators: Kai Wang (Hood-Price Lab), Alphonsus Ng (Heath lab) and Inyoul Lee (Hood-Price Lab)

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.